Meyka Pro banner
Vertex Pharmaceuticals Incorporated

Stay Updated with the Latest Vertex Pharmaceuticals Incorporated VRTX News in Real Time

Find VRTX news now at Meyka AI. Stay informed with the latest Vertex Pharmaceuticals Incorporated stocks updates, including price news, market analysis, and expert insights.

VRTX●NASDAQ
HealthcareBiotechnology
$523.80
$2.39(0.45%)
U.S. Market is Open · 11:59
Google Marks 28th Birthday on September 27 With Nostalgic Doodle
📅 24 hours ago

Google Marks 28th Birthday on September 27 With Nostalgic Doodle

Google turns 28 on September 27, 2026, marking 28 years since Larry Page and Sergey Brin founded the search engine. The company celebrates with a nostalgic Doodle and reflects on its global expansion.

Read more 12
England Bans Deep-Fried School Meals From September 2027
📅 15 days ago

England Bans Deep-Fried School Meals From September 2027

England’s government bans deep-fried foods and cuts desserts in schools from September 2027 to fight obesity. New standards require more vegetables, wholegrains and lentils on menus.

Read more 12
US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge
📅 25 days ago

US Trade Deficit Hits $88.6B in July as AI Chip Imports Surge

US trade deficit reached $88.6 billion in July 2026, up 24% from June. AI-driven demand for semiconductors and computers pushed imports to record highs while exports fell 2.1%.

Read more 12
AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial
📅 1 month ago

AstraZeneca (AZN) and Amgen’s Tezspire Succeeds in Late-Stage Oesophagus Disease Trial

AstraZeneca said Thursday its drug Tezspire met all primary and secondary goals in a late-stage trial. The Phase III CROSSING trial tested Tezspire against placebo in eosinophilic oesophagitis (EoE). AstraZeneca developed the drug jointly with Amgen for this chronic inflammatory oesophagus condition. What the CROSSING Trial Showed The Phase III CROSSING trial evaluated two once-every-four-week…

Read more 12
Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model
📅 1 month ago

Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model

Gaja Alternative IPO’s Grey Market Premium stood at ₹21 as of Thursday, August 20, 2026, 9:45 AM IST. That implies a listing price near ₹181, a 13% premium over the ₹160 upper band. The ₹550 crore issue from Gaja Capital’s asset management arm closes for subscription on August 21. Overall subscription remained modest at 0.30…

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
📅 1 month ago

Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.

Read more 12
AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit
📅 1 month ago

AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit

AstraZeneca has halted a late-stage trial of its lung cancer drug Volrustomig, marking a fresh pipeline setback. The FTSE 100 company said the drug, combined with chemotherapy, was unlikely to improve survival rates. An Independent Data Monitoring Committee recommended stopping the Phase 3 trial after a planned review.  This marks AstraZeneca’s second major trial halt…

Read more 12
2,500 Organizations Hit by LiteLLM Supply Chain Attack in March
📅 2 months ago

2,500 Organizations Hit by LiteLLM Supply Chain Attack in March

LiteLLM supply chain attack in March 2026 exposed 2,500+ organizations and 434,000 CI/CD pipelines. Malicious code ran for 40 minutes, stealing AWS, GCP, and Azure credentials from major tech companies.

Read more 12
Technocraft Ventures IPO Subscription Hits 6.98x on Day 3 as NII Demand Leads
📅 2 months ago

Technocraft Ventures IPO Subscription Hits 6.98x on Day 3 as NII Demand Leads

Technocraft Ventures IPO closed its subscription window Tuesday, August 11, 2026, at 6.98 times overall. Non-institutional investors drove the strongest demand, pushing this EPC infrastructure issue well past full subscription. The ₹251.88 crore mainboard IPO priced shares between ₹200 and ₹212. Strong grey market activity suggests investors expect a solid listing debut this week. Technocraft…

Read more 12

VRTX News FAQ